Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 5
Abstract
Pegylated interferon alpha (PEG-IFN α), a key component of chronic hepatitis C therapy, has been linked to the development of auto-antibodies and autoimmune disease. We report the first case of antimitochondrial antibody (AMA) seroconversion during PEG-INF α based therapy after liver.1-4 transplantation. A fiftyseven year-old man five months after liver transplantation was initiated on hepatitis C triple therapy with PEG-INF α, ribavirin and telaprevir. He had failed previous PEG-IFN α and ribavirin 12 years pre-transplant and his AMA remained negative pre-transplant. After twelve weeks of antiviral therapy, he developed elevated liver enzyme tests associated with an AMA seroconversion to seropositivity. A liver biopsy failed to show histological evidence of primary biliary cirrhosis or graft rejection. He was initiated on urseodeoxycholic acid with subsequent improvement of his liver enzymes. This case demonstrates that despite adequate immunosuppression, AMA seroconversion may occur post-transplant during interferon-based therapy. As AMA seroconversion did not occur during the pre-transplant PEG-IFN therapy, we speculate that donor allograft antigens in combination with PEG-IFN may have been a factor in the post-transplantseroconversion.
Authors and Affiliations
Vladimir Marquez-Azalgara, Trana Hussaini, Siegfried R. Erb, Eric M. Yoshida
Keywords
Related Articles
- EP ID EP78442
- DOI -
- Views 103
- Downloads 0
Treatment with Metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis
Background & Aim. Despite treatment with glucocorticoids, mortality remains high in patients with severe alcoholic hepatitis. Oxidative stress and depletion of mitochondrial glutathione are implicated factors...
Defining renal failure in cirrhosis –Acute kidney injury classification or traditional criteria?
Notch signal protects non-parenchymal cells from ischemia/reperfusion injury in vitro by repressing ROS
Background. We have previously reported that Notch signaling pathway protects hepatocytes from ischemia/ reperfusion (I/R) injury by repressing reactive oxygen species (ROS) production. However, apart from hepatocytes, n...
Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis
Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterised by the immune-mediated destruction of biliary epithelial cells in small intrahepatic bile ducts. The disease is characterised by circulating an...
Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects
Background & aims. Studies about the natural history of hepatitis C virus (HCV) infection report variable progression to cirrhosis depending on study design. Retrospective cross-sectional liver clinic studie...